Company: DHR
Filing Date: 2025-02-20
Form Type: 10-K
Source: 0000313616-25-000043
Chunk: 197

Company: DANAHER CORP /DE/
Filing Date: 2025-02-20
Form: 10-K
Item: Item 5
Chunk 197
---
,674)(620)(965)Distribution from discontinued operations— 2,600 — Payments for repurchase of common stock(5,979)— — All other financing activities(131)(67)(95)Net cash (used in) provided by financing activities for continuing operations(8,385)154 (2,570)Cash distributions to Veralto Corporation, net— (427)— Net cash used in financing activities(8,385)(273)(2,570)Effect of exchange rate changes on cash and equivalents(108)59 (306)Net change in cash and equivalents(3,786)(131)3,409 Beginning balance of cash and equivalents5,864 5,995 2,586 Ending balance of cash and equivalents$2,078 $5,864 $5,995 Supplemental disclosure:Distribution of noncash net assets to Veralto Corporation$— $(1,674)$— 

See the accompanying Notes to the Consolidated Financial Statements.

60

DANAHER CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1.  BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 

Business—Danaher Corporation (“Danaher” or the “Company”) designs, manufactures and markets professional, medical, research and industrial products and services, which are typically characterized by strong brand names, innovative technology and major market positions.  As of December 31, 2024, the Company operates in three business segments: •The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines.  The Company’s solutions support a broad range of biotherapeutics including monoclonal antibodies, recombinant proteins, replacement therapies such as insulin and vaccines, as well as novel cell, gene, mRNA and other nucleic acid therapies. •The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies.  Additionally, the segment provides products and consumables used to filter and remove contaminants from